Cargando…

Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer

OBJECTIVE(S): Patient-derived xenograft (PDX) models have become a valuable tool to evaluate chemotherapeutics and investigate personalized cancer treatment options. The role of PDXs in the study of bladder cancer, especially for improvement of novel targeted therapies, continues to expand. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razzaghdoust, Abolfazl, Muhammadnejad, Samad, Parvin, Mahmoud, Mofid, Bahram, Zangeneh, Masoumeh, Basiri, Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976898/ https://www.ncbi.nlm.nih.gov/pubmed/35432811 http://dx.doi.org/10.22038/IJBMS.2021.59943.13305

Ejemplares similares

Combination of T-DM1 and platinum-based chemotherapy in patient-derived xenograft models of muscle-invasive bladder cancer
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2022)

Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2021)

Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2021)

A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus
por: Mofid, Bahram, et al.
Publicado: (2016)

Spontaneous xenogeneic GvHD in Wilms' tumor Patient‐Derived xenograft models and potential solutions
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2022)

Patient-derived xenograft (PDX) models, applications and challenges in cancer research
por: Abdolahi, Shahrokh, et al.
Publicado: (2022)

AGS cell line xenograft tumor as a suitable gastric adenocarcinoma model: growth kinetic characterization and immunohistochemistry analysis
por: Barati, Tahereh, et al.
Publicado: (2018)

Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model
por: Villanueva, Hugo, et al.
Publicado: (2022)

Triple‐marker immunohistochemical assessment of muscle‐invasive bladder cancer: Is there prognostic significance?
por: Labban, Muhieddine, et al.
Publicado: (2021)

Evaluation of direct intramural injection to the bladder wall as a method for developing orthotopic tumor models
por: Bitaraf, Masoud, et al.
Publicado: (2022)

Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer
por: Ying, Yidie, et al.
Publicado: (2023)

Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study
por: Elwy, Amira Emad, et al.
Publicado: (2019)

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
por: Jäger, Wolfgang, et al.
Publicado: (2014)

Anti‐inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model
por: Hajighasemlou, Saieh, et al.
Publicado: (2022)

Characterization and Validation of Hepatocellular Carcinoma (HCC) Xenograft tumor as a Suitable Liver Cancer Model for Preclinical Mesenchymal Stem Cell Studies
por: Hajighasemlou, Saieh, et al.
Publicado: (2018)

Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma
por: Kim, Bohyun, et al.
Publicado: (2021)

Immunohistochemical Algorithm for the Classification of Muscle-Invasive Urinary Bladder Carcinoma with Lymph Node Metastasis: An Institutional Study
por: Peña, Karla Beatríz, et al.
Publicado: (2022)

Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma
por: Hasan, Abdulkarim, et al.
Publicado: (2023)

Renal mucormycosis following transurethral resection of prostate in the time of COVID-19: Unique imaging features resembling emphysematous pyelonephritis
por: Basiri, Abbas, et al.
Publicado: (2022)

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy
por: Pan, Chong-xian, et al.
Publicado: (2015)

Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy
por: Pardo, Juan Carlos, et al.
Publicado: (2022)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Chemo-immune cell therapy by intratumoral injection of adoptive NK cells with capecitabine in gastric cancer xenograft model
por: Ghazvinian, Zeinab, et al.
Publicado: (2023)

Biological Effect of Modern Fetal Ultrasound Techniques on Human Dermal Fibroblast Cells
por: M., Morshedi, et al.
Publicado: (2019)

An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment
por: Huebner, Doreen, et al.
Publicado: (2017)

Removal of intramural trapped intrauterine device by cystoscopic incision of bladder wall
por: Basiri, Abbas, et al.
Publicado: (2019)

Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis
por: Nakahara, Kozue, et al.
Publicado: (2019)

Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
por: Helal, Duaa S., et al.
Publicado: (2023)

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies
por: Jäger, Wolfgang, et al.
Publicado: (2015)

Characterization of orthotopic xenograft tumor of glioma stem cells (GSCs) on MRI, PET and immunohistochemical staining
por: Liu, Yufei, et al.
Publicado: (2022)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
por: Eminaga, Okyaz, et al.
Publicado: (2023)

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
por: Abbas, Mahmoud, et al.
Publicado: (2023)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
por: Youssef, Ramy F., et al.
Publicado: (2011)

Veritas® bovine pericardium for immediate breast reconstruction: a xenograft alternative to acellular dermal matrix products
por: Mofid, Mehrdad Mark, et al.
Publicado: (2012)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer
por: Holmberg, Lars, et al.
Publicado: (2022)

Laparoscopic Rectopexy with Urinary Bladder Xenograft Reinforcement
por: Mehta, Aradhana, et al.
Publicado: (2017)

Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model
por: Sadighi, Sanambar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5cupckiu9ec3du98dbql1s1mf4